VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2021 | R-CHOP dose intensity and survival outcomes in DLBCL

Chan Yoon Cheah, MBBS, Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia, discusses the results of a systematic review investigating the impact of rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) dose intensity on survival outcomes in patients with diffuse large B-cell lymphoma (DLBCL). Dr Cheah outlines the key findings, highlighting that poorer outcomes were associated with reduced dose intensity in patients up to the age of 80 and in patients without comorbidities. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter